Celltrion's 'Rekkirona', Administration Institutions Expanded to Residential Treatment Centers and Nursing Hospitals (Comprehensive)

Expansion of Administering Institutions Amid Increase in Confirmed Cases

Celltrion 'Rekkironaju' (Photo by Celltrion)

[Asia Economy Reporter Chunhee Lee] The administration of Celltrion's antibody treatment 'Rekkirona' will be expanded to more institutions.

Son Young-rae, head of the Social Strategy Division at the Central Disaster and Safety Countermeasures Headquarters, stated at the regular briefing on the morning of the 24th, "Until now, the antibody treatment (Rekkirona injection) has been supplied to infectious disease specialized hospitals for patient treatment," adding, "From now on, the supply target will be expanded to administer the antibody treatment to mild and moderate patients at residential treatment centers and nursing hospitals."

This is in response to the recent increase in confirmed cases and is a measure to strengthen treatment for mild and moderate patients. The target for administration includes adult confirmed patients over 50 years old who do not require oxygen therapy but have underlying diseases or show signs of pneumonia.

Regarding this policy change, Son said, "Currently approved antibody treatments are recognized and authorized mainly for their effectiveness in preventing the progression to severe illness in moderate or mild patients who have not yet become severe, rather than preventing death in severe patients," and added, "Administering to patients with a high risk of severe progression rather than all patients is a more cost-effective usage."

Son explained the background for expanding the supply target, saying, "Until now, antibody treatments (Rekkirona) have been administered by selecting patients with a risk of severe progression among hospitalized patients mainly at infectious disease specialized hospitals, but as confirmed cases increase, the possibility of such patients existing among confirmed cases at residential treatment centers or nursing hospitals is also increasing."

The supply will begin on the 25th. Nursing hospitals will receive supplies after each city and province assesses the demand by nursing hospital. Residential treatment centers can directly request the medication from Celltrion, and administration will be carried out using either separately installed injection rooms or cooperating hospitals.

This content was produced with the assistance of AI translation services.